Allison Casey

News
Datopotamab Deruxtecan Approved for HR-Positive, HER2-Negative Breast Cancer
01/17/2025
The US Food and Drug Administration approved datopotamab deruxtecan for the treatment of patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy in...
The US Food and Drug Administration approved datopotamab deruxtecan for the treatment of patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy in...
The US Food and Drug...
01/17/2025
Oncology
News
FDA Grants Accelerated Approval for Encorafenib for BRAF V600E Mutant Metastatic Colorectal Cancer
12/20/2024
On December 20, 2024, the US FDA granted an accelerated approval for encorafenib plus cetuximab and modified FOLFOX6 for patients with metastatic colorectal cancer with a BRAF V600E mutation.
On December 20, 2024, the US FDA granted an accelerated approval for encorafenib plus cetuximab and modified FOLFOX6 for patients with metastatic colorectal cancer with a BRAF V600E mutation.
On December 20, 2024, the US FDA...
12/20/2024
Oncology
Conference Coverage
Addition of Palbociclib to Anti-HER2 and Endocrine Therapy As New Standard of Care for Patients With HR-Positive, HER2-Positive Advanced Breast Cancer
12/16/2024
According to final results from the AFT-38 PATINA trial, the addition of palbociclib to anti-HER2 therapy and endocrine therapy demonstrated a statistically significant and clinically meaningful improvement to progression-free survival among...
According to final results from the AFT-38 PATINA trial, the addition of palbociclib to anti-HER2 therapy and endocrine therapy demonstrated a statistically significant and clinically meaningful improvement to progression-free survival among...
According to final results from...
12/16/2024
Oncology
Conference Coverage
Margetuximab Plus Paclitaxel and Pertuzumab for Patients With HER2-Positive Breast Cancer
12/13/2024
According to results from the phase 2 MARGOT trial, margetuximab plus paclitaxel and pertuzumab did not improve the pathological complete response rate compared with trastuzumab plus paclitaxel and pertuzumab among patients with HER2-positive...
According to results from the phase 2 MARGOT trial, margetuximab plus paclitaxel and pertuzumab did not improve the pathological complete response rate compared with trastuzumab plus paclitaxel and pertuzumab among patients with HER2-positive...
According to results from the...
12/13/2024
Oncology
News
Chronic Stress May Contribute to Progression of Metastatic Endometrial Cancer
12/05/2024
Chronic stress may be associated with progression of metastatic disease, particularly among postmenopausal patients with endometrial cancer and lymph node metastasis.
Chronic stress may be associated with progression of metastatic disease, particularly among postmenopausal patients with endometrial cancer and lymph node metastasis.
Chronic stress may be associated...
12/05/2024
Oncology
Conference Coverage
Time of CAR-T Cell Therapy Failure May Predict Outcomes of Bispecific Antibody Therapy Among Patients With Relapsed or Refractory Large B-Cell Lymphoma
12/05/2024
According to a retrospective, real-world study presented at the 2024 ASH Annual Meeting & Exposition, the timing of CAR-T cell therapy failure may predict the outcomes for bispecific antibody therapies for patients with relapsed/refractory...
According to a retrospective, real-world study presented at the 2024 ASH Annual Meeting & Exposition, the timing of CAR-T cell therapy failure may predict the outcomes for bispecific antibody therapies for patients with relapsed/refractory...
According to a retrospective,...
12/05/2024
Oncology
News
Cost-Effectiveness of Multi-Gene Panel Testing for Patients With Advanced Non-Small Cell Lung Cancer
12/05/2024
According to a real-world study, multi-gene panel testing was found to be cost-effective even at higher thresholds for patients with advanced non-small cell lung cancer.
According to a real-world study, multi-gene panel testing was found to be cost-effective even at higher thresholds for patients with advanced non-small cell lung cancer.
According to a real-world study,...
12/05/2024
Oncology
News
Circulating Tumor DNA for Mutation Profiling Among Patients With Advanced Lung Cancer
12/05/2024
According to a study, the use of ctDNA assays may provide complementary information when identifying tumor genomic profiles for patients with advanced lung cancer.
According to a study, the use of ctDNA assays may provide complementary information when identifying tumor genomic profiles for patients with advanced lung cancer.
According to a study, the use of...
12/05/2024
Oncology
Conference Coverage
Potential Mutant-Selective PI3K-Alpha Inhibitor for Patients With PIK3CA-Mutant Solid Tumors And/or HR-Positive, HER2-Negative Breast Cancer
12/03/2024
According to a phase 1/2 study, the PI3K-alpha inhibitor, STX-478, showed promise among patients with PIK3CA-mutant solid tumors and/or HR-positive, HER2-negative breast cancer.
According to a phase 1/2 study, the PI3K-alpha inhibitor, STX-478, showed promise among patients with PIK3CA-mutant solid tumors and/or HR-positive, HER2-negative breast cancer.
According to a phase 1/2 study,...
12/03/2024
Oncology
Conference Coverage
LOXO-783 Demonstrates Proof of Concept of Mutant Selectivity Among Patients With PIK3CA H1047R-Mutant Solid Tumors
12/03/2024
In the PIKASSO-01 trial, LOXO-783 demonstrated a proof of mutant selectivity among patients with PIK3CA H1047R-mutant solid tumors. However, the rate of diarrhea prevented the determination of an optimal preclinical dose.
In the PIKASSO-01 trial, LOXO-783 demonstrated a proof of mutant selectivity among patients with PIK3CA H1047R-mutant solid tumors. However, the rate of diarrhea prevented the determination of an optimal preclinical dose.
In the PIKASSO-01 trial,...
12/03/2024
Oncology

Upcoming Events

February 2 ⁠–⁠ February 5
LLM Winter Symposium
February 7 ⁠–⁠ February 9
Western AF Symposium
February 27 ⁠–⁠ March 1
DCLF
March 17 ⁠–⁠ March 19
GD Solid Tumors
March 22 ⁠–⁠ March 23
NP Institute
March 27 ⁠–⁠ March 30
TCIV
March 31 ⁠–⁠ April 2
Rx summit logo
April 21 ⁠–⁠ April 24
Symposium on Advanced Wound Care
April 30 ⁠–⁠ May 4
WoundCon
May 1 ⁠–⁠ May 3
See Full Calendar

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use